 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LORAZEPAM increase or decrease the risk of myocardial [0m
[34minfarction?[0m
 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LORAZEPAM increase or decrease the risk of myocardial [0m
[32minfarction?[0m
 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LORAZEPAM increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"LORAZEPAM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: LORAZEPAM: adverse_reactions: ADVERSE REACTIONS Most adverse reactions to benzodiazepines, including CNS effects and respiratory depression, are dose dependent, with more severe effects [0m
[31moccurring with high doses. In a sample of about [0m[1;31m3500[0m[31m patients treated for anxiety, the most frequent adverse reaction to lorazepam was sedation [0m[1;31m([0m[1;31m15.9[0m[31m%[0m[1;31m)[0m[31m, followed by dizziness [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m, weakness [0m[1;31m([0m[1;31m4.2[0m[31m%[0m[1;31m)[0m[31m, [0m
[31mand unsteadiness [0m[1;31m([0m[1;31m3.4[0m[31m%[0m[1;31m)[0m[31m. The incidence of sedation and unsteadiness increased with age. LORAZEPAM: adverse_reactions: Other adverse reactions to benzodiazepines, including lorazepam are fatigue, [0m
[31mdrowsiness, amnesia, memory impairment, confusion, disorientation, depression, unmasking of depression, disinhibition, euphoria, suicidal ideation/attempt, ataxia, asthenia, extrapyramidal symptoms, [0m
[31mconvulsions/seizures, tremor, vertigo, eye function/visual disturbance [0m[1;31m([0m[31mincluding diplopia and blurred vision[0m[1;31m)[0m[31m, dysarthria/slurred speech, change in libido, impotence, decreased orgasm; headache, [0m
[31mcoma; respiratory depression, apnea, worsening of sleep apnea, worsening of obstructive pulmonary disease; gastrointestinal symptoms including nausea, change in appetite, constipation, jaundice, [0m
[31mincrease in bilirubin, increase in liver transaminases, increase in alkaline phosphatase; hypersensitivity reactions, anaphylactoid reactions; dermatological symptoms, allergic skin reactions, [0m
[31malopecia; syndrome of inappropriate antidiuretic LORAZEPAM: adverse_reactions: hormone [0m[1;31m([0m[31mSIADH[0m[1;31m)[0m[31m, hyponatremia; thrombocytopenia, agranulocytosis, pancytopenia; hypothermia; and autonomic [0m
[31mmanifestations. Paradoxical reactions, including anxiety, excitation, agitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, and hallucinations may occur. Small decreases[0m
[31min blood pressure and hypotension may occur but are usually not clinically significant, probably being related to the relief of anxiety produced by lorazepam. To report SUSPECTED ADVERSE REACTIONS, [0m
[31mcontact Aurobindo Pharma USA, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m850[0m[31m-[0m[1;31m2876[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: pregnancy: Pregnancy Pregnancy Exposure Registry There is a pregnancy registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including lorazepam, [0m
[31mduring pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m961[0m[31m-[0m[1;31m2388[0m[31m or visiting online at [0m
[4;31mhttps://womensmentalhealth.org/pregnancyregistry/.[0m[31m Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal [0m
[31mwithdrawal [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome and Clinical Considerations [0m[1;31m)[0m[31m. Available data from published observational studies of pregnant women exposed to benzodiazepines do [0m
[31mnot report a clear association with benzodiazepines and major birth defects [0m[1;31m([0m[31msee Data[0m[1;31m)[0m[31m . The background risk of major birth defects and miscarriage for the indicated population is unknown. All [0m
[31mpregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. LORAZEPAM: pregnancy: general population, the estimated risk of major birth defects and of miscarriage [0m
[31min clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Benzodiazepines cross the placenta and may produce respiratory [0m
[31mdepression, hypotonia and sedation in neonates. Monitor neonates exposed to lorazepam during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor [0m
[31mneonates exposed to lorazepam during pregnancy for signs of withdrawal. Manage these neonates accordingly [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome [0m[1;31m)[0m[31m. Data Human Data Published data [0m
[31mfrom observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects. LORAZEPAM: pregnancy: Although early studies [0m
[31mreported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the majority of more recent case-control and cohort [0m
[31mstudies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. Animal Data Reproductive [0m
[31mstudies in animals were performed in mice, rats, and two strains of rabbits. Occasional anomalies [0m[1;31m([0m[31mreduction of tarsals, tibia, metatarsals, malrotated limbs, gastroschisis, malformed skull, and [0m
[31mmicrophthalmia[0m[1;31m)[0m[31m were seen in drug-treated rabbits without relationship to dosage. Although all of these anomalies were not present in the concurrent control group, they have been reported to occur [0m
[31mrandomly in historical controls. At doses of [0m[1;31m40[0m[31m mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits which was not seen at lower doses. LORAZEPAM: precautions: [0m
[31mNursing Mothers Risk Summary Lorazepam is present in breast milk. There are reports of sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. The [0m
[31meffects of lorazepam on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for lorazepam and any potential [0m
[31madverse effects on the breastfed infant from lorazepam or from the underlying maternal condition. Clinical Considerations Infants exposed to lorazepam through breast milk should be monitored for [0m
[31msedation, poor feeding and poor weight gain. Geriatric Use Clinical studies of lorazepam generally were not adequate to determine whether subjects aged [0m[1;31m65[0m[31m and over respond differently than younger [0m
[31msubjects; however, the incidence of sedation and unsteadiness was observed to increase with age [0m[1;31m([0m[31msee ADVERSE REACTIONS [0m[1;31m)[0m[31m. Age does not appear to have a significant effect on lorazepam kinetics [0m[1;31m([0m[31msee [0m
[31mCLINICAL PHARMACOLOGY [0m[1;31m)[0m[31m. LORAZEPAM: precautions: Clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal impairment, should be considered. Greater sensitivity[0m
[1;31m([0m[31me.g., sedation[0m[1;31m)[0m[31m of some older individuals cannot be ruled out. In general, dose selection for an elderly patient should be cautious, and lower doses may be sufficient in these patients [0m[1;31m([0m[31msee DOSAGE [0m
[31mAND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: spl_id         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: dosage_and_administration: DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For optimal results, dose, frequency of administration, and duration of therapy [0m
[31mshould be individualized according to patient response. To facilitate this, [0m[1;31m0.5[0m[31m mg, [0m[1;31m1[0m[31m mg, and [0m[1;31m2[0m[31m mg tablets are available. The usual range is [0m[1;31m2[0m[31m to [0m[1;31m6[0m[31m mg/day given in divided doses, the largest dose [0m
[31mbeing taken before bedtime, but the daily dosage may vary from [0m[1;31m1[0m[31m to [0m[1;31m10[0m[31m mg/day. For anxiety, most patients require an initial dose of [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m mg/day given two times a day or three times a day. For [0m
[31minsomnia due to anxiety or transient situational stress, a single daily dose of [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m mg may be given, usually at bedtime. For elderly or debilitated patients, an initial dosage of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m mg/day in [0m
[31mdivided doses is recommended, to be adjusted as needed and tolerated. LORAZEPAM: dosage_and_administration: The dosage of lorazepam tablets should be increased gradually when needed to help avoid [0m
[31madverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime doses. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of [0m
[31mwithdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the [0m
[31mprevious tapered dosage level. Subsequently decrease the dosage more slowly [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: spl_medguide: â€¢ Store lorazepam tablets in a tightly closed container at room temperature between [0m[1;31m20[0m[31mÂ° to [0m[1;31m25[0m[31mÂ°C [0m[1;31m([0m[1;31m68[0m[31mÂ° to [0m[1;31m77[0m[31mÂ°F[0m[1;31m)[0m[31m. â€¢ Keep lorazepam tablets and all medicines out of the [0m
[31mreach of children. General information about the safe and effective use of lorazepam tablets Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use [0m
[31mlorazepam tablets for a condition for which it was not prescribed. Do not give lorazepam tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your [0m
[31mpharmacist or healthcare provider for information about lorazepam tablets that is written for health professionals. What are the ingredients in lorazepam tablets? Active ingredient: lorazepam Inactive[0m
[31mingredients: anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacrilin potassium. LORAZEPAM: spl_medguide: Distributed by: Aurobindo Pharma USA, Inc. [0m[1;31m279[0m[31m Princeton-Hightstown [0m
[31mRoad East Windsor, NJ [0m[1;31m08520[0m[31m Manufactured by: Aurobindo Pharma Limited Hyderabad-[0m[1;31m500[0m[31m [0m[1;31m032[0m[31m, India For more information, call Aurobindo Pharma USA, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m850[0m[31m-[0m[1;31m2876[0m[31m. This Medication Guide has been [0m
[31mapproved by the U.S. Food and Drug Administration. Repackaged by Preferred Pharmaceuticals, Inc. LORAZEPAM: spl_medguide: Revised: [0m[1;31m06[0m[31m/[0m[1;31m2023[0m[31m         [0m
[31mSOURCE:LORAZEPAM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of myocardial infarction. The adverse reactions listed for lorazepam include[0m
[32mvarious CNS effects, respiratory depression, and other effects such as dizziness, weakness, and unsteadiness, but myocardial infarction is not mentioned as a known adverse reaction.[0m

[32mSOURCE: LORAZEPAM label[0m
[32mEXTRACT_START_END: LORAZEPAM: adverse_reactions: ADVERSE REACTIONS Most adverse[0m[32m...[0m[32mhypotension may occur.[0m
*[1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the LORAZEPAM label does [0m
[34mnot indicate that lorazepam increases or decreases the risk of myocardial infarction. The adverse reactions listed for lorazepam include various CNS effects, respiratory depression, and other effects [0m
[34msuch as dizziness, weakness, and unsteadiness, but myocardial infarction is not mentioned as a known adverse reaction.[0m

[34mSOURCE: LORAZEPAM label[0m
[34mEXTRACT_START_END: LORAZEPAM: adverse_reactions: ADVERSE REACTIONS Most adverse[0m[34m...[0m[34mhypotension may occur.[0m
 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether LORAZEPAM increases or decreases the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of myocardial infarction. The adverse reactions [0m
[32mlisted for lorazepam include various CNS effects, respiratory depression, and other effects such as dizziness, weakness, and unsteadiness, but myocardial infarction is not mentioned as a known adverse[0m
[32mreaction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does LORAZEPAM increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether LORAZEPAM increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of myocardial infarction. The adverse reactions [0m
[34mlisted for lorazepam include various CNS effects, respiratory depression, and other effects such as dizziness, weakness, and unsteadiness, but myocardial infarction is not mentioned as a known adverse[0m
[34mreaction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does LORAZEPAM increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether LORAZEPAM increases or decreases the risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that the available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of myocardial infarction. The adverse reactions listed [0m
[31mfor lorazepam include various CNS effects, respiratory depression, and other effects such as dizziness, weakness, and unsteadiness, but myocardial infarction is not mentioned as a known adverse [0m
[31mreaction.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of myocardial infarction. The adverse reactions listed for lorazepam include various[0m
[32mCNS effects, respiratory depression, and other effects such as dizziness, weakness, and unsteadiness, but myocardial infarction is not mentioned as a known adverse reaction. Therefore, we cannot [0m
[32mdetermine from the FDA label whether lorazepam has any effect on the risk of myocardial infarction.[0m
